Quince Therapeutics, Inc. Common Stock (QNCX) Stock
Key stats
- Market cap
- $32.27M
- EPS (TTM)
- -$142.31
- Volume
- Loading
- 52-week high
- $35.41
- 52-week low
- $0.08
Source: third-party data provider, as of November 13, 2026
Compare with QNCX
Recent news

QNCX Stock Gained 11% Today – Here’s Why Retail Is Speculating A Potential Merger
QNCX Stock Gained 11% Today – Here’s Why Retail Is Speculating A Potential Merger
QNCX

Quince Therapeutics Settles Approximately $16.4 Million of Debt
Quince Therapeutics Settles Approximately $16.4 Million of Debt
QNCX

Quince Therapeutics Engages LifeSci Capital as its Exclusive Financial Advisor to Explore Strategic Alternatives
Quince Therapeutics Engages LifeSci Capital as its Exclusive Financial Advisor to Explore Strategic Alternatives
QNCX

Why Did QNCX Stock Plummet Over 90% Today?
Why Did QNCX Stock Plummet Over 90% Today?
QNCX
Technical indicators
- RSI 14
- 56.90
- MACD 12/26/9
- -0.12
- EMA 9 of MACD
- -0.08
- MACD histogram
- -0.04
- SMA 50
- $30.41
- Price above SMA 50
- EMA 50
- $29.24
- Price above EMA 50
- SMA 200
- $98.79
- Price below SMA 200
- EMA 200
- $144.60
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of October 9, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 4 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
No data available
Debt & Balance Sheet
No data available
Revenue to Profit
No data available
Earnings
No data available
Source: third-party data provider
Latest news

QNCX Stock Gained 11% Today – Here’s Why Retail Is Speculating A Potential Merger
QNCX Stock Gained 11% Today – Here’s Why Retail Is Speculating A Potential Merger
QNCX

Quince Therapeutics Settles Approximately $16.4 Million of Debt
Quince Therapeutics Settles Approximately $16.4 Million of Debt
QNCX

Quince Therapeutics Engages LifeSci Capital as its Exclusive Financial Advisor to Explore Strategic Alternatives
Quince Therapeutics Engages LifeSci Capital as its Exclusive Financial Advisor to Explore Strategic Alternatives
QNCX

Why Did QNCX Stock Plummet Over 90% Today?
Why Did QNCX Stock Plummet Over 90% Today?
QNCX

Quince Therapeutics Announces Topline Results from Pivotal Phase 3 NEAT Clinical Trial of eDSP in Ataxia-Telangiectasia
Quince Therapeutics Announces Topline Results from Pivotal Phase 3 NEAT Clinical Trial of eDSP in Ataxia-Telangiectasia
QNCX

Quince Therapeutics Presents Safety Data from Long-Term eDSP Treatment in Children with Ataxia-Telangiectasia at British Paediatric Neurology Association Annual Meeting
Quince Therapeutics Presents Safety Data from Long-Term eDSP Treatment in Children with Ataxia-Telangiectasia at British Paediatric Neurology Association Annual Meeting
QNCX

Quince Therapeutics Announces Last Patient Last Visit in Phase 3 NEAT Clinical Trial in Patients with Ataxia-Telangiectasia
Quince Therapeutics Announces Last Patient Last Visit in Phase 3 NEAT Clinical Trial in Patients with Ataxia-Telangiectasia
QNCX

Quince Therapeutics Announces Publication of Use of eDSP in Early-Stage Clinical Studies in Pulmonary and Inflammatory Bowel Disorders
Quince Therapeutics Announces Publication of Use of eDSP in Early-Stage Clinical Studies in Pulmonary and Inflammatory Bowel Disorders
QNCX

Quince Therapeutics Selects Option Care Health as Specialty Infusion Therapy Provider for Administration of Lead Asset eDSP
Quince Therapeutics Selects Option Care Health as Specialty Infusion Therapy Provider for Administration of Lead Asset eDSP
QNCX

How to Identify Potentially Profitable Penny Stocks to Buy
How to Identify Potentially Profitable Penny Stocks to Buy
QNCX
About Quince Therapeutics, Inc. Common Stock
No description available.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Dirk Thye M.D. | CEO, Chief Medical Officer & Director | 1970 |
| Mr. Brendan Hannah M.B.A. | Chief Business Officer, COO, Chief Compliance Officer and Principal Financial & Accounting Officer | 1986 |
| Dr. Charles S. Ryan J.D., Ph.D. | President | 1964 |
| Dr. Guenter R. Janhofer M.D., Ph.D. | Chief Scientific Officer | — |
| Dr. Brigette Roberts M.D. | Chief Corporate Affairs Officer & Director | 1975 |
| Dr. Keith R. Fandrick Ph.D. | Head of Technical Operations | 1979 |
| Mr. John C. Militello CPA | Head of Finance | 1973 |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 56.90
- MACD 12/26/9
- -0.12
- EMA 9 of MACD
- -0.08
- MACD histogram
- -0.04
- SMA 50
- $30.41
- Price above SMA 50
- EMA 50
- $29.24
- Price above EMA 50
- SMA 200
- $98.79
- Price below SMA 200
- EMA 200
- $144.60
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of October 9, 2026. Technical data, not a recommendation.
Analyst views
4 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $70.00
- Average
- $72.25
- High
- $77.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022 | -12.4 | -19.4 | -19.4 | -24.5 | -14.7 | |||||||
| 2023 | +36.1 | -1.1 | +64.2 | -13.6 | -4.5 | +5.6 | -18.4 | +8.3 | -13.8 | -9.3 | -8.2 | +9.4 |
| 2024 | +19.2 | -0.8 | -17.2 | -1.8 | -16.2 | -14.8 | +2.7 | -6.8 | +13.0 | +107.7 | +33.1 | -10.1 |
| 2025 | -14.4 | -9.4 | -8.3 | -13.4 | -3.7 | +55.7 | +11.2 | -4.8 | +1.9 | +1.9 | +123.9 | +5.7 |
| 2026 | -94.3 | -27.8 | +0.0 | +31.0 | -13.5 | -18.1 | +39.6 | +30.4 | -3.4 | +3.4 |
Corporate actions
Upcoming
No upcoming corporate actions for QNCX



